When was AnaptysBio founded?

AnaptysBio was founded in 2005 and raised its 1st funding round 2 years after it was founded.

Where is AnaptysBio located?

AnaptysBio is headquartered in San Diego, United States. It is registered at San Diego, California.

How many employees does AnaptysBio have?

As of Jun 30, 2026, the latest employee count at AnaptysBio is 74.

Is AnaptysBio a funded company?

AnaptysBio is a funded company, having raised a total of $85.7M across 7 funding rounds to date. The company's 1st funding round was a $***** Convertible Debt round, raised on Jun 21, 2007.

When was the latest funding round of AnaptysBio?

AnaptysBio's latest funding was a $***** Series D round on Jul 15, 2015, with participation from 6 investors.

What is the annual revenue of AnaptysBio?

Annual revenue of AnaptysBio is between $100M and $500M as on Dec 31, 2025

Where does AnaptysBio rank among its competitors?

AnaptysBio ranks 53rd amongst 5028 active competitors, of which 1215 are funded. It stands 6th in terms of total funding among its competitors. The most recent competitor to raise funding was AstraZeneca, which secured $6.05M in Jul, 2025.

Who are the top competitors of AnaptysBio?

AnaptysBio's top competitors include Jazz Pharmaceuticals, AbbVie and Amgen. Among them, AstraZeneca secured the most recent funding round in July, 2025.

AnaptysBio - 2026 Company Profile, Funding, Competitors & Financials

Company Details

Developer of immunology therapeutics for cancer and inflammatory diseases. The company is developing immune cell modulators, including two checkpoint agonists for autoimmune and inflammatory disease, rosnilimab, its PD-1 agonist, for the treatment of moderate-to-severe rheumatoid arthritis, and ANB032, its BTLA agonist, for the treatment of moderate-to-severe atopic dermatitis.

Website: www.anaptysbio.com/
Social
Registered Address: San Diego, California

Key Metrics

Founded Year

2005

Location

San Diego, United States

Stage

Public

Total Funding

$85.7M in 7 rounds

Latest Funding Round

Series D, Jul 15, 2015, $*****

Investors

Frazier Healthcare Partners & 14 more

Ranked

53^rd among 5028 active competitors

Annual Revenue

$100M - $500M as on Dec 31, 2025

Employee Count

74 as on Jun 30, 2026

Similar Companies

Jazz Pharmaceuticals & 3010 more

Exit Details

Public

View AnaptysBio's full profile

AnaptysBio is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
ANAPTYSBIO INC CIN: 1370053 , United States, Active	Nov 15, 2005	$100M - $500M (As on Dec 31, 2025)	-	-
Anaptysbio, Inc. CIN: 203828755 , United States, Active	Dec 26, 999	-	137 (As on Dec 31, 2024)	-

AnaptysBio got listed on Jan 17, 2017.

Click here to take a look at AnaptysBio's IPO in detail

AnaptysBio has raised a total funding of $85.7M over 7 rounds. Its first funding round was on Jun 21, 2007. Its latest funding round was a Series D round on Jul 15, 2015 for $*****. 6 investors participated in its latest round. AnaptysBio has 15 institutional investors.

Here is the list of recent funding rounds of AnaptysBio:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jul 15, 2015	5310427	Series D	7053315	3393267	1741597	3753830
Oct 08, 2013	5355970	Series B	3012506	8236847	1763461	6375926
Oct 12, 2011	6167942	Series B	1416330	7565237	1698745	3501262

Access funding benchmarks and valuations. Sign up today!

View details of AnaptysBio's funding rounds and investors

AnaptysBio's employee count trend

AnaptysBio has 74 employees as of Jun 26. Here is AnaptysBio's employee count trend over the years:

Uncover AnaptysBio's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of AnaptysBio include Jazz Pharmaceuticals, AbbVie and Amgen. Here is the list of Top 10 competitors of AnaptysBio, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	AbbVie 2012, Chicago (United States), Public	Research-based biopharmaceutical company	$14.7B	Pasadena Private Wealth, Berkshire Hathaway ... & 8 others	81/100
3rd	Amgen 1980, Thousand Oaks (United States), Public	Developer of pharmaceutical products for treating multiple diseases	-	Digital Pharma Lab, Amgen Business Development ... & 11 others	81/100
4th	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, Zhongguancun Development Group ... & 13 others	80/100
5th	Gilead 1987, Foster City (United States), Acquired	Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others	-	Quantinno, Iron Financial & 17 others	80/100
6th	Lilly 1876, Indianapolis (United States), Public	Developer of traditional pharmaceutical medicines	-	Alcor Fund, Digital Pharma Lab & 11 others	75/100
7th	Johnson & Johnson 1886, New Brunswick (United States), Public	Manufacturer and supplier of beauty care products, medical devices, and pharmaceutical products	-	Perkins Wolf & Mc Donnell, Alcor Fund & 16 others	74/100
8th	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, F-Prime Capital & 17 others	73/100
9th	AstraZeneca 1999, Cambridge (United Kingdom), Public	Developer of pharmaceutical medicines for oncology and various chronic diseases	-	Digital Pharma Lab, Columbia Capital & 13 others	73/100
10th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
53rd	AnaptysBio 2005, San Diego (United States), Public	Developer of immunology therapeutics for cancer and inflammatory diseases	$85.7M	BVF Partners, Frazier Life Sciences & 13 others	67/100